Table 3.
This table summarizes the organic Hg exposure from the hepatitis B vaccine preserved with Thimerosal in the female cases with a premature puberty diagnosis compared to the female controls 1, within the database of the VSD.
| Group Examined | Number of Female Cases Diagnosed with Premature Puberty (%) | Number of Female Controls without a Premature Puberty Diagnosis (%) | Odds Ratio (95% CI) | p-Value |
|---|---|---|---|---|
| Group VII | ||||
| 12.5 µg Hg within 1st month | 245 (53.49) | 9997 (38.14) | ||
| 1.865 (1.55–2.245) | <0.00001 | |||
| 0 µg Hg within 1st month | 213 (46.51) | 16,212 (61.86) | ||
| Group VIII | ||||
| 25 µg Hg within first 2 months | 245 (53.73) | 10,009 (38.72) | ||
| 1.838 (1.526–2.213) | <0.00001 | |||
| 0 µg Hg within first 2 months | 211 (46.27) | 15,844 (61.28) | ||
| Group IX | ||||
| 37.5 µg Hg within first 6 months | 53 (81.54) | 1935 (67.49) | ||
| 2.127 (1.131–4.000) | <0.05 | |||
| 0 µg Hg within first 6 months | 12 (18.46) | 932 (32.51) |
1 The control subjects were enrolled continuously from their birth, for a minimum of 5.59 years (the mean age of their initial premature puberty diagnosis plus the SD of mean age of their initial premature puberty diagnosis). Hg = mercury, µg = microgram, SD = standard deviation.